Chemical Identity and Physical Properties

NG,NG-dimethyl-L-arginine, commonly abbreviated as ADMA (asymmetric dimethylarginine), is a naturally occurring amino acid analogue derived from L-arginine. Both nitrogen atoms of the guanidino group carry methyl substituents on the same terminal nitrogen, distinguishing ADMA structurally from its symmetric isomer SDMA (NG,N'G-dimethyl-L-arginine), in which the methyl groups reside on different terminal nitrogens.

ADMA is a white to off-white crystalline solid that is freely soluble in water and insoluble in most organic solvents. It is typically handled as a dihydrochloride salt to improve stability and solubility under aqueous conditions. Stock solutions prepared in sterile water or phosphate-buffered saline (PBS) at concentrations of 10–100 mM are stable for extended periods when stored at −20 °C protected from repeated freeze-thaw cycles.

Key physicochemical parameters to confirm upon receipt include optical rotation (the L-enantiomer is required for biological activity), purity by HPLC, and identity by NMR or mass spectrometry, all of which should be documented in the certificate of analysis (CoA) supplied with Aladdin Scientific product N612426.

Biochemical Mechanism: NOS Inhibition and Nitric Oxide Regulation

Nitric oxide (NO) is synthesized from L-arginine and molecular oxygen by the enzyme family nitric oxide synthase (NOS), which includes the endothelial (eNOS), neuronal (nNOS), and inducible (iNOS) isoforms. ADMA competes directly with L-arginine for binding at the catalytic site of all three isoforms, thereby reducing NO production in a concentration-dependent manner.

ADMA is generated intracellularly when type I protein arginine methyltransferases (PRMT1 being the predominant isoform) methylate arginine residues within proteins. Subsequent proteolysis of these methylated proteins releases free ADMA into the cytoplasm and, ultimately, into plasma. Elevated circulating ADMA concentrations therefore reflect increased PRMT1 activity and/or reduced DDAH activity, both of which are associated with oxidative stress and inflammation.

The ratio of L-arginine to ADMA (the arginine:ADMA ratio) is widely used as a functional index of NOS substrate availability. When this ratio falls, endothelial NO production is impaired, promoting vasoconstriction, platelet aggregation, and pro-inflammatory endothelial phenotype. Researchers supplementing exogenous ADMA in cell culture or animal models therefore achieve a controlled, pharmacologically defined state of reduced NO bioavailability, enabling mechanistic dissection of NOS-dependent pathways.

Experimental Handling and Preparation Guidelines

Reconstitution: Dissolve ADMA (N612426) in sterile, ultrapure water or PBS (pH 7.4) to prepare a concentrated stock solution (10–100 mM). Vortex gently until fully dissolved. For cell-based assays, filter-sterilize through a 0.22 µm membrane prior to addition to culture medium. Avoid DMSO as the primary solvent, as ADMA is insufficiently soluble in most organic solvents.

Storage: Store the solid compound at −20 °C in a tightly sealed, desiccated container away from light. Aqueous stock solutions should be aliquoted to avoid freeze-thaw degradation; single-use aliquots stored at −80 °C are recommended for long-term stability. Once thawed, use within 24 hours and do not refreeze.

Working concentrations: Typical in vitro concentrations used to inhibit NOS range from 0.1 µM (reflecting physiological endogenous levels) to 1 mM (pharmacological/supraphysiological inhibition). In vivo infusion protocols vary widely; consult primary literature for species-specific dosing. Always include an L-arginine rescue control (equimolar or excess L-arginine) to confirm NOS-specific effects.

Contamination and controls: Confirm the absence of endotoxin in preparations used for cell or animal studies, particularly for experiments involving endothelial or immune cells. Include vehicle controls (solvent alone) and, where appropriate, a positive NOS inhibitor control such as L-NAME (Nω-nitro-L-arginine methyl ester) for comparative reference.

Research Applications and Experimental Models

Cardiovascular and vascular biology: ADMA is the most extensively studied endogenous NOS inhibitor. It is applied exogenously to primary endothelial cells (e.g., HUVECs), smooth muscle cells, and cardiomyocytes to model endothelial dysfunction, impaired vasodilation, and hypertensive vascular phenotypes. Measurement of intracellular or released NO (Griess reagent, DAF-FM fluorescence, or chemiluminescence) before and after ADMA treatment provides a direct functional readout.

Metabolic disease models: ADMA accumulates in conditions of insulin resistance, chronic kidney disease, and hyperhomocysteinemia. Researchers use exogenous ADMA to recapitulate reduced NO bioavailability in these contexts and to test pharmacological interventions (e.g., DDAH overexpression, antioxidants, or substrate supplementation with L-arginine or L-citrulline).

Biomarker quantification studies: Analytical measurement of endogenous ADMA in plasma, urine, or tissue lysates is typically performed by HPLC with fluorescence detection, LC-MS/MS, or ELISA-based kits. Stable isotope-labeled ADMA standards are required as internal controls for mass spectrometric quantification; researchers should confirm appropriate internal standard availability when designing such assays.

Gene expression and signalling: Beyond direct NOS inhibition, ADMA treatment has been reported to activate downstream stress-response pathways including NF-κB, PKC, and MAPK cascades, independently of NO reduction. These pleiotropic effects should be considered when interpreting data, and parallel experiments using the inactive isomer SDMA as a negative control are strongly recommended to distinguish NO-dependent from NO-independent effects.

Quality, Safety, and Regulatory Considerations

Purity and quality assurance: For biological studies, researchers should use ADMA of ≥98% purity (HPLC) to minimise confounding effects from related arginine analogues such as SDMA or monomethyl-L-arginine (L-NMMA). The certificate of analysis for Aladdin Scientific N612426 should be reviewed prior to use to confirm lot-specific purity, identity, and water content.

Safety profile: ADMA is not classified as a hazardous substance under standard laboratory chemical regulations; however, standard laboratory safety practices apply. Avoid inhalation of dust or aerosols. Wear appropriate personal protective equipment (gloves, lab coat, eye protection) when weighing or handling concentrated solutions. Refer to the Safety Data Sheet (SDS) supplied with the product for comprehensive hazard information.

Disposal: Dispose of ADMA-containing solutions and contaminated materials in accordance with local institutional and governmental regulations for chemical waste. ADMA is a naturally occurring endogenous metabolite, but bulk disposal must still follow appropriate chemical waste protocols.

Regulatory note: ADMA is not a controlled substance. It does not require special import/export permits in most jurisdictions; however, researchers should confirm applicable local regulations when ordering internationally.